Overview

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

Status:
ENROLLING_BY_INVITATION

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Phase:

PHASE2

Details

Lead Sponsor:

Biohaven Therapeutics Ltd.